Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas

Abstract

	•Mesothelin expression is significantly higher in gastric and colorectal cancers than normal tissues.
	•hYP218 CAR T cells demonstrate strong anti-tumour activity against mesothelin-positive gastric and colorectal carcinomas.
	•Activated hYP218 CAR T cells persist in the tumour microenvironment and retain their cytotoxic activity.
	•Addition of pembrolizumab in larger tumours enhance CAR T cell efficacy.

Keywords

anti-PD1 / CAR T cell / colorectal cancer / gastric cancer / mesothelin / pembrolizumab / xenograft cancer model

References

[1] Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635-648.

[2] Hossain MS, Karuniawati H, Jairoun AA, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). 2022;14(7).

[3] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. The Lancet. 2019;394(10207):1467-1480.

[4] Li K, Zhang A, Li X, et al. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188615.

[5] Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264-279.

[6] Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669-685.

[7] Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, et al. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197.

[8] Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nature Rev Drug Dis. 2021;20(7):531-550.

[9] Schmidts A, Maus MV. Making CAR T Cells a solid option for solid tumors. Front Immunol. 2018;9:2593.

[10] Long KB, Young RM, Boesteanu AC, et al. CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success. Front Immunol. 2018;9:2740-2740.

[11] June CH, Sadelain M. Chimeric antigen receptor therapy. New Eng J Med. 2018;379(1):64-73.

[12] Kronig MN, Wehrli M, Salas-Benito D, et al. “Hurdles race for CAR T-cell therapy in digestive tract cancer”. Immunol Rev. 2023;320(1):100-119.

[13] Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93(1):136-140.

[14] Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10(12):3937-3942.

[15] Hassan R, Alewine C, Mian I, et al. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer. 2020;126(22):4936-4947.

[16] Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13(17):5144-5149.

[17] Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927-5936.

[18] Hassan R, Blumenschein GR Jr, Moore KN, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol. 2020;38(16):1824-1835.

[19] Hassan R, Alley E, Kindler H, et al. Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res. 2019;25(19):5787-5798.

[20] Haas AR, Tanyi JL, O’Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27(11):1919-1929.

[21] Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748-2763.

[22] O’Hara M, Stashwick C, Haas AR, et al. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy. 2016;8(4):449-460.

[23] Thomas A, Chen Y, Steinberg SM, et al. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget. 2015;6(13):11694-11703.

[24] Inaguma S, Wang Z, Lasota J, et al. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. Oncotarget. 2017;8(16):26744-26754.

[25] Malla M, Deshmukh SK, Wu S, et al. Comprehensive characterization of mesothelin expression in colorectal cancer. J Clin Oncol. 2023;41(4):245-245.

[26] Inoue S, Tsunoda T, Riku M, et al. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncol Lett. 2020;19(3):1741-1750.

[27] Saha S, Mukherjee C, Basak D, et al. High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer. Adv Cancer Biol-Metast. 2023;7:100098.

[28] Tomar S, Zhang J, Khanal M, et al. Development of highly effective anti-mesothelin hYP218 chimeric antigen receptor T cells with increased tumor infiltration and persistence for treating solid tumors. Mol Cancer Ther. 2022;21(7):1195-1206.

[29] Aronowitz JA, Lockhart RA, Hakakian CS. Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. SpringerPlus. 2015;4(1):713.

[30] Hassan R, Thomas A, Alewine C, et al. Mesothelin immunotherapy for cancer: ready for prime time?. J Clin Oncol. 2016;34(34):4171-4179.

[31] Einama T, Homma S, Kamachi H, et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 2012;107(1):137-142.

[32] Hombach AA, Schildgen V, Heuser C, et al. T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol. 2007;178(7):4650-4657.

[33] Kortekaas KE, Santegoets SJ, Sturm G, et al. CD39 identifies the CD4(+) tumor-specific T-cell population in human cancer. Cancer Immunol Res. 2020;8(10):1311-1321.

[34] Isaacs JF, Degefu HN, Chen T, et al. CD39 is expressed on functional effector and tissue-resident memory CD8+ T cells. J Immunol. 2024;213(5):588-599.

[35] Tang N, Cheng C, Zhang X, et al. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4).

[36] Pellino A, Riello E, Nappo F, et al. Targeted therapies in metastatic gastric cancer: current knowledge and future perspectives. World J Gastroenterol. 2019;25(38):5773-5788.

[37] Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1(1):26-31.

[38] Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112-120.

[39] Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27(11):1418-1428.

[40] Ito T, Kajino K, Abe M, et al. ERC/mesothelin is expressed in human gastric cancer tissues and cell lines. Oncol Rep. 2014;31(1):27-33.

[41] Weidemann S, Gagelmann P, Gorbokon N, et al. Mesothelin expression in human tumors: a tissue microarray study on 12, 679 tumors. Biomedicines. 2021;9(4):397.

[42] Han SH, Joo M, Kim H, et al. mesothelin expression in gastric adenocarcinoma and its relation to clinical outcomes. J Pathol Transl Med. 2017;51(2):122-128.

[43] Zhang Z, Jiang D, Yang H, et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death & Disease. 2019;10(7):476.

[44] Zhang Q, Liu G, Liu J, et al. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. Mol Ther Oncolytics. 2021;20:556-568.

[45] Zhang Z, Jiang D, Yang H, et al. Correction: modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 2020;11(4):235.

[46] Ye J, Liu Q, He Y, et al. Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer. J Transl Med. 2024;22(1):171.

[47] Cao B, Liu M, Huang J, et al. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int J Biol Sci. 2021;17(14):3850-3861.

[48] Zou F, Tan J, Liu T, et al. The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29(5):1794-1807.

[49] Meng J, Tan JYT, Joseph CR, et al. The prognostic value of CD39 as a marker of tumor-specific T cells in triple-negative breast cancer in Asian women. Lab Invest. 2024;104(3):100303.

[50] Fraessle SP, Tschulik C, Effenberger M, et al. Activation-inducible CAR expression enables precise control over engineered CAR T cell function. Communications Biology. 2023;6(1):604.

[51] Hassan R, Butler M, O’Cearbhaill RE, et al. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nat Med. 2023;29(8):2099-2109.

[52] Wang Z, Li N, Feng K, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188-2198.

[53] Heczey A, Louis CU, Savoldo B, et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Molecular Therapy. 2017;25(9):2214-2224.

[54] Wu Y, Yu XZ. Modelling CAR-T therapy in humanized mice. EBioMedicine. 2019;40:25-26.

[55] Hu X, Manner K, DeJesus R, et al. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat Commun. 2023;14(1):2020.

[56] Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133-146.

[57] Haas AR, Golden RJ, Litzky LA, et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol Ther. 2023;31(8):2309-2325.

RIGHTS & PERMISSIONS

2024. This article is a U.S. Government work and is in the public domain in the USA. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.